Matches in SemOpenAlex for { <https://semopenalex.org/work/W10130044> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W10130044 endingPage "10" @default.
- W10130044 startingPage "1607" @default.
- W10130044 abstract "Platinum-based chemotherapy has been proved effective in patients with advanced non-small cell lung cancer (NSCLC). This study evaluated the effectiveness and safety of first-line chemotherapy with gemcitabine plus cisplatin (GEM-Cis) 3-week regimen in routine care of Chinese patients with advanced NSCLC.Two hundred and twenty-one patients with NSCLC stage IIIb or IV were enrolled and 209 were eligible for effectiveness and safety analysis. The median age was 58 (range 29 to 79) years. The percents of cases in stage IV and stage IIIb were 52.2% and 47.8%; of Karnofsky performance score (KPS) less than 80 and 80 - 100 were 37.3% and 62.7% and of adeno-cancer and non-adeno-cancer were 59.8% and 40.2%. The average number of completed chemotherapy cycles was three. Measures of effectiveness included clinical benefit, significant clinical response (SCR) and adverse effects of GEM-Cis in the treatment of NSCLC at stages IIIb/IV.KPS increased from 79 +/- 9 at baseline to 86 +/- 10 after chemotherapy (P < 0.01). Lung cancer symptom scale (LCSS) score of pain, dyspnea and cough increased from 77 +/- 24, 74 +/- 22 and 63 +/- 19 to 92 +/- 15, 90 +/- 14 and 86 +/- 15, respectively (P < 0.01). The clinical benefit rate was 85.2% [95% confidence interval (CI) 80.3% - 90.0%]. The SCR was 89.5% (95% CI 85.3% - 93.7%). Median survival time was 7.8 months (95% CI 7.1 months-9.1 months). Sixty-four patients (30.6%) experienced an adverse effect that was deemed clinically significant. Only one patient (0.5%) was hospitalized due to chemotherapy related adverse effects. Life-threatening toxicity was observed in two patients (1.0%).First-line chemotherapy with GEM-Cis in the routine care of Chinese patients with advanced NSCLC is effective and safe." @default.
- W10130044 created "2016-06-24" @default.
- W10130044 creator A5008736377 @default.
- W10130044 creator A5012278873 @default.
- W10130044 creator A5027378939 @default.
- W10130044 creator A5027922054 @default.
- W10130044 creator A5062627395 @default.
- W10130044 creator A5070745750 @default.
- W10130044 creator A5086438849 @default.
- W10130044 date "2004-11-01" @default.
- W10130044 modified "2023-09-22" @default.
- W10130044 title "Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small cell lung cancer: a prospective observational study." @default.
- W10130044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15569473" @default.
- W10130044 hasPublicationYear "2004" @default.
- W10130044 type Work @default.
- W10130044 sameAs 10130044 @default.
- W10130044 citedByCount "0" @default.
- W10130044 crossrefType "journal-article" @default.
- W10130044 hasAuthorship W10130044A5008736377 @default.
- W10130044 hasAuthorship W10130044A5012278873 @default.
- W10130044 hasAuthorship W10130044A5027378939 @default.
- W10130044 hasAuthorship W10130044A5027922054 @default.
- W10130044 hasAuthorship W10130044A5062627395 @default.
- W10130044 hasAuthorship W10130044A5070745750 @default.
- W10130044 hasAuthorship W10130044A5086438849 @default.
- W10130044 hasConcept C126322002 @default.
- W10130044 hasConcept C141071460 @default.
- W10130044 hasConcept C143998085 @default.
- W10130044 hasConcept C146357865 @default.
- W10130044 hasConcept C151730666 @default.
- W10130044 hasConcept C197934379 @default.
- W10130044 hasConcept C2776256026 @default.
- W10130044 hasConcept C2776694085 @default.
- W10130044 hasConcept C2780258809 @default.
- W10130044 hasConcept C2781413609 @default.
- W10130044 hasConcept C44249647 @default.
- W10130044 hasConcept C71924100 @default.
- W10130044 hasConcept C86803240 @default.
- W10130044 hasConceptScore W10130044C126322002 @default.
- W10130044 hasConceptScore W10130044C141071460 @default.
- W10130044 hasConceptScore W10130044C143998085 @default.
- W10130044 hasConceptScore W10130044C146357865 @default.
- W10130044 hasConceptScore W10130044C151730666 @default.
- W10130044 hasConceptScore W10130044C197934379 @default.
- W10130044 hasConceptScore W10130044C2776256026 @default.
- W10130044 hasConceptScore W10130044C2776694085 @default.
- W10130044 hasConceptScore W10130044C2780258809 @default.
- W10130044 hasConceptScore W10130044C2781413609 @default.
- W10130044 hasConceptScore W10130044C44249647 @default.
- W10130044 hasConceptScore W10130044C71924100 @default.
- W10130044 hasConceptScore W10130044C86803240 @default.
- W10130044 hasIssue "11" @default.
- W10130044 hasLocation W101300441 @default.
- W10130044 hasOpenAccess W10130044 @default.
- W10130044 hasPrimaryLocation W101300441 @default.
- W10130044 hasRelatedWork W2045806517 @default.
- W10130044 hasRelatedWork W2349270370 @default.
- W10130044 hasRelatedWork W2367470826 @default.
- W10130044 hasRelatedWork W2378715638 @default.
- W10130044 hasRelatedWork W2381460883 @default.
- W10130044 hasRelatedWork W2412379702 @default.
- W10130044 hasRelatedWork W2413941024 @default.
- W10130044 hasRelatedWork W2439707001 @default.
- W10130044 hasRelatedWork W2442673159 @default.
- W10130044 hasRelatedWork W3032349186 @default.
- W10130044 hasVolume "117" @default.
- W10130044 isParatext "false" @default.
- W10130044 isRetracted "false" @default.
- W10130044 magId "10130044" @default.
- W10130044 workType "article" @default.